Tear Film Osmolarity, Ocular Surface Disease and Glaucoma: A Review

Curr Med Chem. 2019;26(22):4241-4252. doi: 10.2174/0929867326666190725160621.

Abstract

Glaucoma is the second leading cause of blindness in the world, affecting more than 60 million people globally. In order to reduce the progression of the disease, both medical and surgical treatments are used. Frequent side effects of both treatments include a range of modifications of the ocular surface grouped as the Ocular Surface Disease (OSD), which include Dry Eye Disease (DED). DED and other OSD negatively impact on the success of anti-glaucoma treatments and reduce the adherence to medical therapies. Tear film osmolarity (TFO) is a relatively novel test which has become a hallmark of DED. The aim of this paper was to review the association between OSD, DED and glaucoma in view of published TFO data, and to discuss future fields of research and treatments on the topic of glaucoma iatrogenic damage.

Keywords: Tear film osmolarity; benzalkonium chloride; blindness; dry eye disease; glaucoma; ocular surface disease..

Publication types

  • Review

MeSH terms

  • Animals
  • Antihypertensive Agents / chemistry
  • Antihypertensive Agents / pharmacology*
  • Corneal Diseases / drug therapy*
  • Glaucoma / drug therapy*
  • Humans
  • Osmolar Concentration
  • Preservatives, Pharmaceutical / chemistry
  • Preservatives, Pharmaceutical / pharmacology*
  • Surface Properties
  • Tears / drug effects*

Substances

  • Antihypertensive Agents
  • Preservatives, Pharmaceutical